ATNM
Price
$1.17
Change
-$0.06 (-4.88%)
Updated
Feb 21 closing price
Capitalization
36.5M
19 days until earnings call
NONOF
Price
$87.40
Change
+$4.40 (+5.30%)
Updated
Feb 21 closing price
Capitalization
393.7B
Ad is loading...

ATNM vs NONOF

Header iconATNM vs NONOF Comparison
Open Charts ATNM vs NONOFBanner chart's image
Actinium Pharmaceuticals
Price$1.17
Change-$0.06 (-4.88%)
Volume$124.12K
Capitalization36.5M
Novo-Nordisk A/S
Price$87.40
Change+$4.40 (+5.30%)
Volume$12.91K
Capitalization393.7B
ATNM vs NONOF Comparison Chart
Loading...
ATNM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATNM vs. NONOF commentary
Feb 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATNM is a Hold and NONOF is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Feb 24, 2025
Stock price -- (ATNM: $1.17 vs. NONOF: $87.40)
Brand notoriety: ATNM and NONOF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATNM: 50% vs. NONOF: 17%
Market capitalization -- ATNM: $36.5M vs. NONOF: $393.7B
ATNM [@Biotechnology] is valued at $36.5M. NONOF’s [@Biotechnology] market capitalization is $393.7B. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATNM’s FA Score shows that 0 FA rating(s) are green whileNONOF’s FA Score has 2 green FA rating(s).

  • ATNM’s FA Score: 0 green, 5 red.
  • NONOF’s FA Score: 2 green, 3 red.
According to our system of comparison, NONOF is a better buy in the long-term than ATNM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATNM’s TA Score shows that 3 TA indicator(s) are bullish while NONOF’s TA Score has 6 bullish TA indicator(s).

  • ATNM’s TA Score: 3 bullish, 4 bearish.
  • NONOF’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, NONOF is a better buy in the short-term than ATNM.

Price Growth

ATNM (@Biotechnology) experienced а +1.74% price change this week, while NONOF (@Biotechnology) price change was +11.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.27%. For the same industry, the average monthly price growth was +3.99%, and the average quarterly price growth was +2.35%.

Reported Earning Dates

ATNM is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (+4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NONOF($394B) has a higher market cap than ATNM($36.5M). NONOF YTD gains are higher at: 1.745 vs. ATNM (-7.143). NONOF has higher annual earnings (EBITDA): 137B vs. ATNM (-44.15M). NONOF has more cash in the bank: 26.3B vs. ATNM (78.7M). ATNM has less debt than NONOF: ATNM (1.71M) vs NONOF (103B). NONOF has higher revenues than ATNM: NONOF (290B) vs ATNM (81K).
ATNMNONOFATNM / NONOF
Capitalization36.5M394B0%
EBITDA-44.15M137B-0%
Gain YTD-7.1431.745-409%
P/E RatioN/A27.65-
Revenue81K290B0%
Total Cash78.7M26.3B0%
Total Debt1.71M103B0%
FUNDAMENTALS RATINGS
ATNM vs NONOF: Fundamental Ratings
ATNM
NONOF
OUTLOOK RATING
1..100
1266
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
30
Undervalued
PROFIT vs RISK RATING
1..100
10044
SMR RATING
1..100
9814
PRICE GROWTH RATING
1..100
8864
P/E GROWTH RATING
1..100
10092
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NONOF's Valuation (30) in the null industry is somewhat better than the same rating for ATNM (71) in the Biotechnology industry. This means that NONOF’s stock grew somewhat faster than ATNM’s over the last 12 months.

NONOF's Profit vs Risk Rating (44) in the null industry is somewhat better than the same rating for ATNM (100) in the Biotechnology industry. This means that NONOF’s stock grew somewhat faster than ATNM’s over the last 12 months.

NONOF's SMR Rating (14) in the null industry is significantly better than the same rating for ATNM (98) in the Biotechnology industry. This means that NONOF’s stock grew significantly faster than ATNM’s over the last 12 months.

NONOF's Price Growth Rating (64) in the null industry is in the same range as ATNM (88) in the Biotechnology industry. This means that NONOF’s stock grew similarly to ATNM’s over the last 12 months.

NONOF's P/E Growth Rating (92) in the null industry is in the same range as ATNM (100) in the Biotechnology industry. This means that NONOF’s stock grew similarly to ATNM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATNMNONOF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 6 days ago
73%
Bullish Trend 6 days ago
86%
Momentum
ODDS (%)
Bullish Trend 6 days ago
73%
Bearish Trend 6 days ago
68%
MACD
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 6 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
70%
Bearish Trend 6 days ago
62%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
76%
Bearish Trend 6 days ago
66%
Advances
ODDS (%)
Bullish Trend 6 days ago
74%
Bullish Trend 18 days ago
74%
Declines
ODDS (%)
Bearish Trend 17 days ago
87%
Bearish Trend 10 days ago
57%
BollingerBands
ODDS (%)
N/A
Bullish Trend 6 days ago
89%
Aroon
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
75%
View a ticker or compare two or three
Ad is loading...
ATNM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL245.55-0.28
-0.11%
Apple
BTC.X96258.000000-319.757800
-0.33%
Bitcoin cryptocurrency
SPY599.94-10.44
-1.71%
SPDR® S&P 500® ETF Trust
GME26.42-0.62
-2.29%
GameStop Corp
TSLA337.80-16.60
-4.68%
Tesla

ATNM and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATNM has been loosely correlated with GBIO. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ATNM jumps, then GBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATNM
1D Price
Change %
ATNM100%
-4.88%
GBIO - ATNM
47%
Loosely correlated
-0.78%
AURA - ATNM
40%
Loosely correlated
-1.57%
ABOS - ATNM
36%
Loosely correlated
+0.72%
PRLD - ATNM
36%
Loosely correlated
-3.50%
NTLA - ATNM
34%
Loosely correlated
-0.65%
More

NONOF and

Correlation & Price change

A.I.dvisor tells us that NONOF and ATNM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NONOF and ATNM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NONOF
1D Price
Change %
NONOF100%
+5.30%
ATNM - NONOF
31%
Poorly correlated
-4.88%
NVO - NONOF
31%
Poorly correlated
+5.18%
LABFF - NONOF
23%
Poorly correlated
N/A
UCBJY - NONOF
21%
Poorly correlated
+0.40%
COEP - NONOF
14%
Poorly correlated
-4.62%
More